Wordt geladen...
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
INTRODUCTION: Limited comparative effectiveness data for rituximab (RTX) versus natalizumab (NTZ), fingolimod (FTY), and dimethyl fumarate (DMF) for the treatment of multiple sclerosis (MS) exist. METHODS: Clinician‐reported data on patients prescribed RTX, NTZ, FTY, or DMF for the treatment of MS a...
Bewaard in:
| Gepubliceerd in: | Ann Clin Transl Neurol |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7480919/ https://ncbi.nlm.nih.gov/pubmed/32767538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51111 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|